**Chapter 5**

*The Burden of Respiratory Syncytial Virus Infection in the Young*

virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. The Journal of Infectious Diseases.

[70] Glenn GM et al. Safety and immunogenicity of a Sf9 insect cellderived respiratory syncytial virus fusion protein nanoparticle vaccine.

Vaccine. 2013;**31**(3):524-532

2015;**33**(47):6488-6492

2017;**35**(30):3749-3759

[72] August A et al. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine.

[71] Glenn GM et al. Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs. Vaccine.

2016;**213**(3):411-422

[62] Stensballe LG et al. Respiratory

antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. The Journal of Allergy and Clinical Immunology.

respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. The Journal of Pediatrics.

[64] Walsh EE et al. Virus-specific antibody, viral load, and disease severity in respiratory syncytial virus infection. The Journal of Infectious Diseases.

[65] Rossey I et al. Clinical potential

antibodies. Trends in Microbiology.

[66] Brown PM et al. Prenatal exposure to respiratory syncytial virus alters postnatal immunity and airway smooth muscle contractility during early-life reinfections. PLoS One.

[67] Broadbent L et al. Respiratory syncytial virus, an ongoing medical dilemma: An expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials. Influenza and Other Respiratory Viruses.

[68] Falloon J et al. An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults. The Journal of

[69] Glenn GM et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial

Infectious Diseases. 2017;

of prefusion RSV F-specific

syncytial virus neutralizing

[63] Glezen WP et al. Risk of

2009;**123**(2):398-403

1981;**98**(5):708-715

2018;**218**(2):208-217

2018;**26**(3):209-219

2017;**12**(2):e0168786

2015;**9**(4):169-178

**216**:1362-1370

**76**
